Panacea Biotec shares soar 15% to 52-week high on launch of EU-funded DENSTAR project; what investors need to know

At around 11:04 AM, the stock was trading 15.06% higher at ₹636.15 per equity share.

The scrip has gained 47% in the past week and 63% over the month. On a year-to-date basis, it has advanced 68%.

Starting on June 1, the DENSTAR project will work to advance the licensure of the dengue vaccine DengiAll in sub-Saharan Africa and to facilitate its broader global use, according to a regulatory filing dated June 8.

The four-year initiative is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking (GH EDCTP3 JU) and is supported by the European Union.

The initiative aligns with the EDCTP3 mission to combat Neglected Tropical Diseases (NTDs), including dengue fever, and seeks to reduce the disease burden across Africa, the filing read.

The DENSTAR project is coordinated by the "Sclavo Vaccines Association", a non-profit organisation based in Siena, Italy, devoted to supporting vaccine research and development in developing countries.

The consortium unites 10 Partners from nine countries across Europe, Africa, the United States, India and South Korea.

DENSTAR comprises universities, research organisations, a biotech company and a non-profit organisation, bringing together experts, researchers, regulators, and healthcare practitioners.

Panacea Biotec, developer of DengiAll, a tetravalent dengue vaccine targeting all four virus serotypes and currently in late-stage development in India, is a key partner.

The diverse and complementary consortium embodies a public-private partnership, fully aligned with the DENSTAR project's goal of promoting the broader use of DengiAll in Africa and globally, contributing to equitable access to safe and effective dengue prevention tools, it said.

The DENSTAR consortium will conduct Phase I/III studies in healthy African adults and children to confirm that the DengiAll vaccine works safely and effectively in this population, paving the way for regulatory approval and deployment in Sub-Saharan Africa.

“The project will also address critical knowledge gaps by evaluating vaccine efficacy against Dengue Virus serotype 4 (DENV-4) using Controlled Human Infection Models (CHIMs), an area where no vaccine has yet demonstrated protection, making this research essential to strengthening scientific evidence and public confidence in future vaccine wider use,” the filing read.

The vaccine offers several advantages for widespread use, particularly in lower- and middle-income countries, Panacea Biotec said.

It is single-dose, cost-efficient to manufacture, and suitable for large-scale deployment and technology transfer, it stated, adding that unlike other dengue vaccines, it requires no prior serological testing, making it a practical and scalable solution for diverse populations and equitable immunization strategies.

Commenting on the development, Dr. Khalid Ali Syed, Chief Scientific Officer of Panacea Biotec Limited, said: “The project efforts are expected to have a lasting impact on global health, extending beyond the project's immediate scope and duration by reducing the dengue burden, improving quality of life, alleviating pressure on health systems, and upholding the universal right to a healthy, productive life."

Panacea Biotec has a total market capitalisation of ₹3,662.79 crore as of June 9, 2026, according to data on the NSE.